Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 16 for:    sage | Major Depressive Disorder
Previous Study | Return to List | Next Study

A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03864614
Recruitment Status : Recruiting
First Posted : March 6, 2019
Last Update Posted : September 2, 2021
Sponsor:
Information provided by (Responsible Party):
Sage Therapeutics

Brief Summary:
This is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult participants with MDD.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Drug: SAGE-217 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1550 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With SAGE-217 in Adult Subjects With Major Depressive Disorder
Actual Study Start Date : February 27, 2019
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : February 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: SAGE-217 Drug: SAGE-217
SAGE-217




Primary Outcome Measures :
  1. Safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by the incidence and severity of adverse events. [ Time Frame: 52 Weeks ]
  2. Safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by the incidence of clinically significant changes from baseline in clinical laboratory measures. [ Time Frame: 52 Weeks ]
  3. Safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by the incidence of clinically significant changes from baseline in vital signs. [ Time Frame: 52 Weeks ]
  4. Safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by the incidence of clinically significant changes from baseline in electrocardiograms (ECGs). [ Time Frame: 52 Weeks ]
  5. The safety and tolerability of the initial treatment with SAGE-217 and/or re-treatment with SAGE-217, as assessed by suicidal ideation and behavior using the Columbia Suicide Severity Rating Scale (C-SSRS). [ Time Frame: 52 Weeks ]
    The C-SSRS consists of a baseline evaluation that assesses the lifetime experience of the participants with suicidal ideation and behavior, and a post-baseline evaluation that focuses on suicidality since the last study visit. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe).


Secondary Outcome Measures :
  1. The need for re-treatment with SAGE-217 as assessed by the time to first re-treatment. [ Time Frame: Up to 52 weeks ]
  2. The need for re-treatment with SAGE-217 as assessed by the number of participants achieving the requirements for re-treatment. [ Time Frame: Up to 52 weeks ]
  3. The need for re-treatment with SAGE-217 as assessed by the number of re-treatment cycles for each participant. [ Time Frame: Up to 52 weeks ]
  4. The response of initial treatment and/or re-treatment as assessed by change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) score. [ Time Frame: Up to 52 weeks ]
    The 17-item HAM-D scale is used for measuring severity of depression. The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression.

  5. The response of initial treatment and/or re-treatment as assessed by percent of participants achieving HAM-D response at the end of each 14-day treatment period, defined as a ≥50% reduction in HAM-D score from baseline. [ Time Frame: Up to 52 weeks ]
    The 17-item HAM-D scale is used for measuring severity of depression. The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression.

  6. The response of initial treatment and/or re-treatment as assessed by percent of participants achieving HAM-D remission at the end of each 14-day treatment (initial and/or re-treatment) period, defined as HAM-D total score ≤7. [ Time Frame: Up to 52 weeks ]
    The 17-item HAM-D scale is used for measuring severity of depression. The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression.

  7. The response of initial treatment and/or re-treatment as assessed by percent of participants achieving Clinical Global Impression - Improvement (CGI-I) score. [ Time Frame: Up to 52 weeks ]
    The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition posttreatment. The Investigator will rate the participant's total improvement compared to baseline, whether or not it is due entirely to drug treatment. Response choices include: 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse.

  8. The response of initial treatment and/or re-treatment as assessed by change from baseline in Clinical Global Impression - Severity (CGI-S) score. [ Time Frame: Up to 52 weeks ]
    The CGI-S uses a 7-point Likert scale to rate the severity of the participant's mental illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating as 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=extremely ill.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participant has a diagnosis of MDD as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Clinical Trial Version (SCID-5-CT), with symptoms that have been present for at least a 4-week period.
  2. Participant is in good physical health and has no clinically significant findings, as determined by the Investigator, on physical examination, 12-lead electrocardiogram (ECG), or clinical laboratory tests.
  3. Participant has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score of ≥28 and a HAM-D total score of ≥20 at Screening and Day 1 (prior to dosing).

Exclusion Criteria:

  1. Participant has attempted suicide associated with the current episode of MDD.
  2. Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
  3. Participant has had vagus nerve stimulation, electroconvulsive therapy, or has taken ketamine (including esketamine) within the current major depressive episode.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03864614


Contacts
Layout table for location contacts
Contact: Robert Lasser, MD, MBA 617-949-5176 robert.lasser@sagerx.com

Locations
Hide Hide 54 study locations
Layout table for location information
United States, Alabama
Sage Investigational Site Recruiting
Dothan, Alabama, United States, 36303
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Arizona
Sage Investigational Site Recruiting
Phoenix, Arizona, United States, 85012
Contact       clinicaltrialsinquiry@sagerx.com   
United States, California
Sage Investigational Site Recruiting
Anaheim, California, United States, 92805
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Costa Mesa, California, United States, 92626
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Glendale, California, United States, 91206
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Irvine, California, United States, 92614
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Los Alamitos, California, United States, 90720
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Oceanside, California, United States, 92056
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Orange, California, United States, 92868
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Riverside, California, United States, 92503
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
San Diego, California, United States, 92103
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Temecula, California, United States, 92591
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Colorado
Sage Investigational Site Recruiting
Colorado Springs, Colorado, United States, 80910
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Active, not recruiting
Denver, Colorado, United States, 80209
United States, Connecticut
Sage Investigational Site Recruiting
Cromwell, Connecticut, United States, 06416
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Norwich, Connecticut, United States, 06360
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Florida
Sage Investigational Site Active, not recruiting
Brandon, Florida, United States, 33511
Sage Investigational Site Recruiting
Coral Springs, Florida, United States, 33067
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Jacksonville, Florida, United States, 32256
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Active, not recruiting
Miami, Florida, United States, 33122
Sage Investigational Site Recruiting
Orlando, Florida, United States, 32801
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Orlando, Florida, United States, 32807
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Pensacola, Florida, United States, 32502
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Georgia
Sage Investigational Site Recruiting
Alpharetta, Georgia, United States, 30022
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Atlanta, Georgia, United States, 30331
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Marietta, Georgia, United States, 30060
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Savannah, Georgia, United States, 31405
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Illinois
Sage Investigational Site Recruiting
Chicago, Illinois, United States, 60634
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Chicago, Illinois, United States, 60640
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Maryland
Sage Investigational Site Recruiting
Towson, Maryland, United States, 21204
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Massachusetts
Sage Investigational Site Recruiting
Watertown, Massachusetts, United States, 02472
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Michigan
Sage Investigational Site Recruiting
Ann Arbor, Michigan, United States, 48109
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Missouri
Sage Investigational Site Recruiting
Saint Charles, Missouri, United States, 63304
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Nebraska
Sage Investigational Site Recruiting
Lincoln, Nebraska, United States, 68526
Contact       clinicaltrialsinquiry@sagerx.com   
United States, New Jersey
Sage Investigational Site Recruiting
Cherry Hill, New Jersey, United States, 08002
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational site Recruiting
Marlton, New Jersey, United States, 08053
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Princeton, New Jersey, United States, 08540
Contact       clinicaltrialsinquiry@sagerx.com   
United States, New Mexico
Sage Investigational Site Recruiting
Albuquerque, New Mexico, United States, 87109
Contact       clinicaltrialsinquiry@sagerx.com   
United States, New York
Sage Investigational Site Recruiting
Brooklyn, New York, United States, 11229
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Brooklyn, New York, United States, 11235
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Mount Kisco, New York, United States, 10549
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Ohio
Sage Investigational Site Recruiting
Beachwood, Ohio, United States, 44122
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Cincinnati, Ohio, United States, 45212
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational site Recruiting
Cincinnati, Ohio, United States, 45215
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Cincinnati, Ohio, United States, 45219
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
North Canton, Ohio, United States, 44720
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Oklahoma
Sage Investigational Site Recruiting
Oklahoma City, Oklahoma, United States, 73112
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Pennsylvania
Sage Investigational Site Recruiting
Plymouth Meeting, Pennsylvania, United States, 19462
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Texas
Sage Investigational Site Active, not recruiting
Austin, Texas, United States, 78737
Sage Investigational Site Recruiting
Austin, Texas, United States, 78759
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Dallas, Texas, United States, 75231
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Houston, Texas, United States, 77081
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Wichita Falls, Texas, United States, 76309
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Washington
Sage Investigational Site Recruiting
Bellevue, Washington, United States, 98007
Contact       clinicaltrialsinquiry@sagerx.com   
Sponsors and Collaborators
Sage Therapeutics
Layout table for additonal information
Responsible Party: Sage Therapeutics
ClinicalTrials.gov Identifier: NCT03864614    
Other Study ID Numbers: 217-MDD-303
First Posted: March 6, 2019    Key Record Dates
Last Update Posted: September 2, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Data sharing will be consistent with the Results submission policy of ClinicalTrials.gov

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms